-
公开(公告)号:US4602027A
公开(公告)日:1986-07-22
申请号:US501012
申请日:1983-06-06
申请人: Kanji Meguro , Takeshi Fujita
发明人: Kanji Meguro , Takeshi Fujita
IPC分类号: A61K31/42 , A61K31/421 , A61P3/08 , A61P3/10 , C07D263/32 , C07D263/40 , C07D263/30
CPC分类号: C07D263/32 , C07D263/40
摘要: A compound of the formula: ##STR1## wherein R.sup.1 is (A) a group of the formula, ##STR2## wherein R.sup.4 is H, a halogen or trifluoromethyl group, or (B) a group of the formula, ##STR3## wherein n is 0 or an integer of 1 to 3; R.sup.5 is H or an alkyl group of 1 to 6 carbon atoms; respective R.sup.6 and R.sup.7 are an alkyl group of 1 to 6 carbon atoms, an alkenyl group of 2 to 6 carbon atoms, a cycloalkyl group of 3 to 7 carbon atoms, or a cycloalkenyl group of 5 to 7 carbon atoms; R.sup.6 and R.sup.7 may be combined with the neighboring carbon atom to represent a cycloalkyl group of 3 to 7 carbon atoms; a cycloalkenyl group of 5 to 7 carbon atoms, a bicycloalkyl group of 7 to 10 carbon atoms, or a bicycloalkenyl group of 7 to 10 carbon atoms; R.sup.2 is an alkyl group of 1 to 6 carbon atoms; and R.sup.3 is H, an alkyl group of 1 to 6 carbon atoms or an aralkyl group, or a pharmaceutically acceptable salt thereof. The compound has hypoglycemic, glucose tolerance improving and insulin sensitivity potentiating activities.
摘要翻译: 下式的化合物,其中R 1是(A)下式的基团,其中R 4是H,卤素或三氟甲基,或(B)下式的基团,其中n 为0或1〜3的整数; R5是H或1-6个碳原子的烷基; 各自的R 6和R 7为碳原子数1〜6的烷基,碳原子数2〜6的烯基,碳原子数3〜7的环烷基或碳原子数为5〜7的环烯基。 R6和R7可以与相邻的碳原子结合,代表3-7个碳原子的环烷基; 具有5至7个碳原子的环烯基,7至10个碳原子的双环烷基或7至10个碳原子的双环烯基; R2是1-6个碳原子的烷基; R3为H,1〜6个碳原子的烷基或芳烷基,或其药学上可接受的盐。 该化合物具有降血糖,葡萄糖耐量提高和胰岛素敏感性增强活性。
-
公开(公告)号:US4596816A
公开(公告)日:1986-06-24
申请号:US485433
申请日:1983-04-15
申请人: Kanji Meguro , Takeshi Fujita
发明人: Kanji Meguro , Takeshi Fujita
IPC分类号: A61K31/42 , A61K31/421 , A61P3/08 , A61P3/10 , C07D263/32
CPC分类号: C07D263/32
摘要: Novel oxazole derivatives of the formula ##STR1## (wherein R.sup.1 is hydrogen or a straight, branched or cyclic alkyl group of 1 to 6 carbon atoms, R.sup.2 is hydrogen, halogen, trifluoromethyl, or a straight, branched or cyclic alkylthio of 1 to 3 carbon atoms, and n is 1 or 2) or pharmaceutically acceptable salts or esters thereof are synthesized through several routes. The derivatives have hypoglycemic, glucose tolerance improving and insulin sensitivity increasing activities and are of value as antidiabetic drugs.
摘要翻译: 式(IMAGE)的新型恶唑衍生物(其中,R 1为氢或1〜6个碳原子的直链,支链或环状烷基,R2为氢,卤素,三氟甲基或1〜3的直链,支链或环状烷硫基) 碳原子,n为1或2)或其药学上可接受的盐或酯通过若干途径合成。 衍生物具有降血糖,葡萄糖耐量提高和胰岛素敏感性增加的活性,并且作为抗糖尿病药物具有价值。
-
公开(公告)号:US07622469B2
公开(公告)日:2009-11-24
申请号:US10539234
申请日:2003-12-16
申请人: Shirou Maeda , Toshiko Kita , Kanji Meguro
发明人: Shirou Maeda , Toshiko Kita , Kanji Meguro
IPC分类号: A61K31/53 , A01N43/66 , A61K31/47 , A01N43/42 , C07D251/00 , C07D251/10
CPC分类号: A61Q17/005 , A61K8/4966 , A61K31/53 , A61K2800/52 , C07D251/10
摘要: The present invention relates to an antibacterial agent, which comprises, as an active ingredient, a compound represented by the following general formula (1): or a pharmaceutically acceptable salt thereof.
摘要翻译: 本发明涉及一种抗菌剂,其包含作为活性成分的由以下通式(1)表示的化合物或其药学上可接受的盐。
-
公开(公告)号:USRE36575E
公开(公告)日:2000-02-15
申请号:US948515
申请日:1997-10-10
申请人: Kanji Meguro , Takeshi Fujita , Chitoshi Hatanaka , Satoru Ooi
发明人: Kanji Meguro , Takeshi Fujita , Chitoshi Hatanaka , Satoru Ooi
IPC分类号: A61K31/44 , A61P3/08 , C07D213/30 , C07D213/46 , C07D417/12
CPC分类号: C07D213/30 , C07D417/12
摘要: A compound of the formula: ##STR1## (wherein R.sup.1 is hydrogen or a lower alkyl) can be produced advantageously by (1) reacting a compound of the formula: ##STR2## (wherein R.sup.1 has the meaning given above) with a halogenating agent or sulfonyl halide to give a compound of the formula: ##STR3## (wherein R.sup.1 has the meaning given above and X is a halogen or an alkyl- or aryl-sulfonyloxy), (2) reacting the resulting compound with a compound of the formula: ##STR4## to give a compound of the formula: ##STR5## (wherein R.sup.1 has the meaning given above), (3) reacting the resulting compound with a compound of the formula: ##STR6## to give a compound of the formula: ##STR7## (wherein R.sup.1 has the meaning given above), and (4) subjecting the resulting compound to catalytic reduction.
摘要翻译: 可以有利地通过(1)使下式化合物(其中R 1具有上面给出的含义)与卤化剂或磺酰卤反应得到下式的化合物(其中R 1是氢或低级烷基),得到 化合物:其中R1具有上面给出的含义,X是卤素或烷基 - 或芳基 - 磺酰氧基),(2)使所得化合物与下式化合物反应:得到下式化合物: (其中R1具有上述含义),(3)使所得化合物与下式化合物反应:得到下式化合物:其中R 1具有上述含义,和(4)使所得化合物 催化还原。
-
25.
公开(公告)号:US5362742A
公开(公告)日:1994-11-08
申请号:US646735
申请日:1991-02-01
申请人: Kanji Meguro , Hitoshi Ikeda
发明人: Kanji Meguro , Hitoshi Ikeda
IPC分类号: A61K31/47 , A61P3/06 , A61P9/00 , A61P9/08 , A61P9/10 , A61P43/00 , C07D215/38 , C07D405/12 , C07D407/12 , C07D417/12
CPC分类号: C07D215/38 , C07D405/12 , C07D417/12
摘要: A quinoline derivative of the formula (I): ##STR1## wherein each phenyl ring of A and B can have one or more substituents; X is ##STR2## (R.sup.1 is a hydrogen atom, a lower alkyl group or a lower alkoxy group) or ##STR3## (R.sup.2 is a hydrogen atom or a lower alkyl group); Y is --(CH.sub.2).sub.m --(m is 0, 1 or 2) or --CH.dbd.CH--, Z is a group of the formula: ##STR4## wherein each phenyl ring of C and D can have one or more substituents, R.sup.3 and R.sup.4 are each a hydrogen or halogen atom, or a lower alkyl, lower alkoxy, lower acyloxy, lower alkoxycarbonyloxy, N,N-di-lower alkylcarbamoyloxy, optionally esterified carboxy or hydroxyl group, R.sup.5 is a halogen atom, or a lower alkyl, lower alkoxy, lower acyloxy, lower alkoxycarbonyloxy, N,N-di-lower alkylcarbamoyloxy, optionally esterified carboxy or hydroxyl group, R.sup.6 and R.sup.7 are each a hydrogen atom or a lower alkyl group, and n, o and p are each 1 or 2; l is 0 or 1; or its salt, which is useful as a drug for atherosclerosis.
摘要翻译: PCT No.PCT / JP90 / 01617 Sec。 371日期1991年2月1日 102(e)1991年2月1日PCT 1990年12月10日PCT PCT。 出版物WO91 / 09017 日期:1992年6月27日。式(I)的喹啉衍生物:B可以具有一个或多个取代基; X为
(R 1为氢原子,低级烷基或低级烷氧基)或者(R 2为氢原子或低级烷基)。 Y是 - (CH 2)m - (m是0,1或2)或-CH = CH-,Z是下式的基团:其中每个C和D的苯环可以具有一个 或更多取代基,R 3和R 4各自为氢或卤素原子,或低级烷基,低级烷氧基,低级酰氧基,低级烷氧基羰基氧基,N,N-二低级烷基氨基甲酰氧基,任意酯化的羧基或羟基,R5为卤素原子 ,或低级烷基,低级烷氧基,低级酰氧基,低级烷氧基羰基氧基,N,N-二低级烷基氨基甲酰氧基,任意酯化的羧基或羟基,R6和R7各自为氢原子或低级烷基,n,o和 p分别为1或2; l为0或1; 或其盐,其可用作动脉粥样硬化的药物。 -
公开(公告)号:US5278186A
公开(公告)日:1994-01-11
申请号:US671796
申请日:1991-04-02
申请人: Kanji Meguro , Hiroyuki Tawada , Hitoshi Ikeda
发明人: Kanji Meguro , Hiroyuki Tawada , Hitoshi Ikeda
IPC分类号: C07D311/12 , C07D311/14 , C07D311/16 , C07D335/06 , A61F31/355
CPC分类号: C07D335/06 , C07D311/12 , C07D311/14 , C07D311/16
摘要: A chromene derivative of the formula (I) ##STR1## wherein each ring of A and B can have one or more substituents; X is an oxygen atom or sulfur atom, Y is an oxygen or sulfur atom or H.sub.2, Z is a bond, --NH-- or a saturated or unsaturated lower alkylene group and R is a hydrocarbon radical which is unsubstituted or substituted, or its salt, which is useful as a drug for atherosclerosis.
摘要翻译: PCT No.PCT / JP91 / 00172 Sec。 371日期:1991年4月2日 102(e)日期1991年4月2日PCT 1991年2月2日PCT PCT。 公开号WO91 / 12249 日期:1991年8月22日。A和B的每个环可具有一个或多个取代基的式(I)的色烯衍生物(*化学结构*)(I) X是氧原子或硫原子,Y是氧或硫原子或H 2,Z是键,-NH-或饱和或不饱和的低级亚烷基,R是未取代或取代的烃基,或其盐 ,其可用作动脉粥样硬化的药物。
-
公开(公告)号:US4812570A
公开(公告)日:1989-03-14
申请号:US73695
申请日:1987-07-14
申请人: Kanji Meguro , Takeshi Fujita , Chitoshi Hatanaka , Satoru Ooi
发明人: Kanji Meguro , Takeshi Fujita , Chitoshi Hatanaka , Satoru Ooi
IPC分类号: A61K31/44 , A61P3/08 , C07D213/30 , C07D213/46 , C07D417/12 , C07D409/12
CPC分类号: C07D213/30 , C07D417/12
摘要: A compound of the formula: ##STR1## (wherein R.sup.1 is hydrogen or a lower alkyl) can be produced advantageously by (1) reacting a compound of the formula: ##STR2## (wherein R.sup.1 has a meaning given above) with a halogenating agent or sulfonyl halide to give a compound of the formula: ##STR3## (wherein R.sup.1 has a meaning given above and X is a halogen or an alkyl- or aryl-sulfonyloxy), (2) reacting the resulting compound with a compound of the formula: ##STR4## to give a compound of the formula: (wherein R.sup.1 has the meaning given above), (3) reacting the resulting compound with a compound of the formula: ##STR5## to give a compound of the formula: ##STR6## (wherein R.sup.1 has the meaning given above), and (4) subjecting the resulting compound to catalytic reduction.
-
公开(公告)号:US4581322A
公开(公告)日:1986-04-08
申请号:US681762
申请日:1984-12-14
摘要: A method for developing a silver halide photographic material in the presence of an amino compound represented by the following general formula (I) or the salt thereof to increase photographic speed and/or gamma without being attended by a concomitant increase in generation of fog: ##STR1## wherein R.sup.1 represents an alkyl group, an aryl group, an aralkyl group or a cycloalkyl group; R.sup.2 and R.sup.3, which may be the same or different, each represents a hydrogen atom, an alkyl group, an alkenyl group, an aryl group, an aralkyl group or an alkylcarbonyl group, or R.sup.2 and R.sup.3 may combine with each other and form a ring; and A represents a divalent aliphatic linkage group.
摘要翻译: 在由下列通式(I)表示的氨基化合物或其盐的存在下显影卤化银照相材料的方法,以增加摄影速度和/或γ,而不伴随着雾的产生的伴随增加: (I)其中R1表示烷基,芳基,芳烷基或环烷基; R 2和R 3可以相同或不同,各自表示氢原子,烷基,烯基,芳基,芳烷基或烷基羰基,或者R 2和R 3可以彼此结合形成 环; A表示二价脂肪连接基团。
-
公开(公告)号:US5254565A
公开(公告)日:1993-10-19
申请号:US807813
申请日:1991-12-16
申请人: Kanji Meguro , Hitoshi Ikeda
发明人: Kanji Meguro , Hitoshi Ikeda
IPC分类号: C07D215/38 , C07D215/60 , A61K31/47
CPC分类号: C07D215/38 , C07D215/60
摘要: Quinoline derivatives of the formula: ##STR1## , wherein R is hydrogen, alkyl or aralkyl; m and n are 0 or 1, and each of rings A, B and C can have substituents, which are useful as inhibitors for acyl-CoA:Cholesterolacyltransferase.
-
公开(公告)号:US4898947A
公开(公告)日:1990-02-06
申请号:US291782
申请日:1988-12-29
申请人: Kanji Meguro , Takeshi Fujita , Chitoshi Hatanaka , Satoru Ooi
发明人: Kanji Meguro , Takeshi Fujita , Chitoshi Hatanaka , Satoru Ooi
IPC分类号: A61K31/44 , A61P3/08 , C07D213/30 , C07D213/46 , C07D417/12
CPC分类号: C07D213/30 , C07D417/12
摘要: A compound of the formula: ##STR1## (wherein R.sup.1 is hydrogen or a lower alkyl) can be produced advantageously by (1) reacting a compound of the formula: ##STR2## (wherein R.sup.1 has the meaning given above) with a halogenating agent or sulfonyl halide to give a compound of the formula: ##STR3## (wherein R.sup.1 has the meaning given above and X is a halogen or an alkyl- or aryl-sulfonyloxy), (2) reacting the resulting compound with a compound of the formula: ##STR4## to give a compound of the formula: ##STR5## (wherein R.sup.1 has the meaning given above), (3) reacting the resulting compound with a compound of the formula: ##STR6## to give a compound of the formula: ##STR7## (wherein R.sup.1 has the meaning given above), and (4) subjecting the resulting compound to catalytic reduction.
-
-
-
-
-
-
-
-
-